InvestorsHub Logo
icon url

toofun

06/10/16 5:02 PM

#204517 RE: Hike #204514

The Ivory Tower speaks:

"A single product in a big class of products with the same chemical isn't going to make a dent in oxycodone use," Walsh said.

Well maybe we need to start with one...SequestOx

"I'd be open to seeing an efficacy trial in this specific chronic pain population," Passik said

Well this is an immediate release opiate is that study going to happen unless its for breakthrough pain??

But, good to see the FDA is showing some consistency in this madness. I had no idea there were this many me too opiates in the pipeline. Must mean there is money in it. lol
icon url

Couch

06/10/16 8:36 PM

#204554 RE: Hike #204514

The MIGHTY Purdue couidn't even formulate a solid IR ADT product!

NOW that is funny!!

PURDUE might as well pony up $5.2 billion for an Elite buyout.